Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that it has licensed ex-US rights to Day One Biopharmaceuticals' (Nasdaq:DAWN) tovorafenib for paediatric low-grade glioma (pLGG), the most common form of childhood brain cancer.
Tovorafenib is FDA-approved for relapsed or refractory pLGG with BRAF alterations, a condition affecting over half of pLGG cases globally. The drug addresses an unmet need for targeted treatments outside the United States.
Under the agreement Day One will receive USD111m upfront, including USD71m cash and USD40m equity investment, plus up to USD350m in milestones and tiered double-digit royalties.
Ipsen will be responsible for the regulatory and commercial activities for tovorafenib in all territories outside of the United States.
Day One will maintain exclusive global development and US commercial rights for tovorafenib.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation